Overview

Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection

Status:
Recruiting

Trial end date:
2024-08-01

Target enrollment:

Participant gender:

Summary

This is a randomized, open label, multicenter Phase 2 study investigating the safety and antiviral activity of AB-729 in combination with ongoing NA therapy and short courses of Peg-IFNα-2a in subjects with CHB.

Phase:

Phase 2

Details

Lead Sponsor:

Arbutus Biopharma Corporation

Treatments:

Interferon alpha-2
Interferon-alpha
Interferons
Peginterferon alfa-2a